Congenital Hyperinsulinism Treatment Market

Congenital Hyperinsulinism Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Congenital Hyperinsulinism Treatment Market

• Demand and Growth Drivers
  • Improving neonatal screening and genetic diagnostic capabilities are expanding identification of congenital hyperinsulinism, increasing the patient population requiring pharmacological and surgical management.
  • Drug therapy accounts for 68.5% of the treatment method segment, reflecting the frontline role of diazoxide, somatostatin analogs, and glucagon in managing excessive insulin secretion.
  • Hospitals represent the primary treatment setting, with specialty clinics holding 41.8% of end-use share for ongoing management and monitoring.
• Product and Segment View
  • Drug therapy holds 68.5% of the treatment method segment in 2026, confirming pharmacological management as the primary treatment approach before surgical intervention is considered.
  • Hospitals account for 74.2% of the application segment, reflecting the critical care requirements for initial diagnosis and stabilization.
  • Hospital pharmacies hold 38.9% of distribution share, with retail and online pharmacies serving maintenance medication needs.
• Geography and Competitive Outlook
  • China (5.8%) and India (5.7%) are expected to lead growth, driven by expanding neonatal care infrastructure and improving rare disease diagnostic capabilities.
  • Germany (5.6%) reflects advanced neonatal intensive care and established rare disease treatment frameworks.
  • Xeris Pharmaceuticals holds an estimated 20.0% market share, leveraging its glucagon-based treatment portfolio for hypoglycemia management.
• Analyst Opinion
  • The congenital hyperinsulinism treatment market is evolving from limited pharmacological options toward a more diversified therapeutic landscape as novel drug candidates and targeted therapies progress through clinical development.
  • Growth reflects expanding neonatal screening programs that identify more patients requiring treatment, combined with increasing rare disease healthcare investment globally.
  • Pharmaceutical companies with established endocrine and metabolic disease portfolios are positioned to serve this market through existing and pipeline products.
  • Treatment decisions between medical and surgical approaches remain complex, with drug therapy serving as the first-line option and pancreatectomy reserved for medication-resistant cases.
  • Companies developing targeted potassium channel modulators and novel insulin secretion inhibitors are expected to reshape competitive dynamics beyond 2030.

Key Takeaways, Market Size, and Forecast

• The congenital hyperinsulinism treatment market was valued at USD 112.4 million in 2025.
• By 2036, the congenital hyperinsulinism treatment market is expected to be worth USD 213.37 million.
• From 2026 to 2036, the market is projected to expand at a CAGR of 6%.
• The market is projected to create an incremental opportunity of USD 94.23 million between 2026 and 2036.
• In 2026, drug therapy is expected to account for 68.5% of the treatment method segment, driven by diazoxide and octreotide as frontline pharmacological management options.
• Hospitals are expected to lead the end-user segment with a 74.2% share.
• China (5.8%) and India (5.7%) are among the fastest-growing markets globally.

Congenital Hyperinsulinism Treatment Market Definition

The Congenital Hyperinsulinism Treatment Market encompasses pharmaceutical products, surgical interventions, and therapeutic approaches used in managing congenital hyperinsulinism, a rare genetic condition characterized by excessive insulin secretion from pancreatic beta cells resulting in persistent hypoglycemia.

Congenital Hyperinsulinism Treatment Market Inclusions

Market scope includes all commercially traded treatments categorized by treatment method (drug therapy, surgery), application (hospitals, clinics, others), end use (hospitals, specialty clinics, home care settings), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies). The revenue range spans 2026 to 2036.

Congenital Hyperinsulinism Treatment Market Exclusions

The scope does not include general diabetes management products, general hypoglycemia treatment for non-congenital conditions, or neonatal intensive care equipment not specific to hyperinsulinism treatment.

Congenital Hyperinsulinism Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with industry participants, product specialists, and distribution channel experts across key markets.
• Desk Research: Combined industry publications, regulatory filings, trade association data, and manufacturer disclosures.
• Market Sizing and Forecasting: Bottom-up aggregation across product segments and regional adoption curves, validated through top-down cross-referencing.
• Data Validation: Cross-checked quarterly against industry production data and manufacturer-reported figures.

Why is the Congenital Hyperinsulinism Treatment Market Growing?

• Neonatal screening programs and genetic testing are improving diagnosis rates for congenital hyperinsulinism, expanding the identified patient population requiring pharmacological and surgical management.
• Novel therapeutic approaches including targeted potassium channel modulators and glucagon-based treatments are expanding the pharmacological toolkit beyond traditional diazoxide therapy.
• China (5.8%) and India (5.7%) lead growth, reflecting expanding neonatal care infrastructure and improving rare disease diagnostic capabilities across large population bases.

Demand for congenital hyperinsulinism treatments reflects improving diagnostic capabilities in neonatal and pediatric healthcare settings. Genetic testing for mutations in ABCC8, KCNJ11, and related genes enables earlier and more precise diagnosis, allowing clinicians to initiate targeted treatment protocols. Neonatal screening programs that detect persistent hypoglycemia facilitate diagnosis in the first days of life.

Drug therapy (68.5% of treatment method) serves as the first-line management approach. Diazoxide, the primary pharmacological treatment, is effective in approximately 50% of cases. Somatostatin analogs (octreotide, lanreotide) serve diazoxide-resistant patients, while glucagon infusion provides emergency hypoglycemia management. Surgical pancreatectomy is reserved for medication-resistant focal or diffuse disease.

Geographic demand patterns reflect differences in neonatal care infrastructure and rare disease diagnostic capabilities. Developed markets provide comprehensive screening and treatment, while developing markets in Asia and Latin America are expanding diagnostic reach, creating new patient identification and treatment opportunities.

Market Segmentation Analysis

• Drug therapy holds 68.5% of treatment method share, confirming pharmacological management as the primary approach.
• Hospitals account for 74.2% of application demand, reflecting critical care requirements for diagnosis and initial treatment.
• Specialty clinics represent 41.8% of end-use, indicating ongoing management in specialized endocrine and metabolic care settings.

The Congenital Hyperinsulinism Treatment Market is segmented by treatment method (drug therapy, surgery), application (hospitals, clinics, others), end use (hospitals, specialty clinics, home care settings), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies).

Insights into the Drug Therapy Treatment Method

In 2026, drug therapy is expected to represent 68.5% of the treatment method segment. Diazoxide serves as the first-line treatment for most patients, with somatostatin analogs and glucagon-based therapies providing alternatives for diazoxide-resistant cases.

Novel drug candidates targeting specific genetic subtypes of congenital hyperinsulinism are progressing through clinical development, potentially expanding pharmacological treatment options.

Insights into the Hospital Application

Hospitals account for 74.2% of application demand. Congenital hyperinsulinism requires neonatal intensive care for initial stabilization, specialized endocrine evaluation for diagnosis, and surgical capability for medication-resistant cases.

Specialty clinics serve long-term management after initial hospital-based diagnosis and treatment stabilization.

Congenital Hyperinsulinism Treatment Market Drivers, Restraints, and Opportunities

• Expanding neonatal screening and genetic testing programs are increasing patient identification rates across developed and developing markets.
• Limited treatment options and variable drug response rates constrain management outcomes, with diazoxide being effective in only approximately 50% of cases.
• Novel targeted therapies and precision medicine approaches offer opportunities to improve treatment efficacy and expand the pharmacological toolkit.

The Congenital Hyperinsulinism Treatment Market benefits from improving diagnostics and pipeline drug development. Limited treatment options and drug resistance present constraints, while precision medicine and novel therapeutics offer growth opportunities.

Neonatal Screening Expansion

Demand is shaped by expanding neonatal screening programs that detect persistent hypoglycemia in the first days of life. Early identification enables prompt treatment initiation, improving outcomes and creating a larger treated patient population.

Limited Treatment Options and Drug Resistance

Growth is constrained by the limited pharmacological options available for congenital hyperinsulinism. Diazoxide resistance affects approximately half of patients, requiring alternative treatments that carry higher side-effect profiles or surgical intervention.

Novel Targeted Therapeutic Development

Adoption is supported by pharmaceutical research into targeted therapies that address specific genetic subtypes of congenital hyperinsulinism. Potassium channel modulators, GLP-1 receptor antagonists, and genotype-specific approaches are advancing through clinical trials.

Precision Medicine and Genetic Subtyping

Growth reflects the application of precision medicine approaches to congenital hyperinsulinism management. Genetic subtyping enables clinicians to select treatments based on the specific mutation profile, improving response rates and reducing unnecessary surgical interventions.

Analysis of Congenital Hyperinsulinism Treatment Market By Key Countries

Country	CAGR
China	5.8%
India	5.7%
Germany	5.6%
Brazil	5.5%
USA	5.4%

• China leads growth at 5.8% CAGR, driven by expanding neonatal care infrastructure and improving rare disease diagnostics.
• India follows at 5.7%, supported by growing healthcare investment and neonatal screening program development.
• Germany (5.6%) sustains growth through advanced neonatal care and established rare disease treatment frameworks.

The global Congenital Hyperinsulinism Treatment Market is expected to expand at a CAGR of 6% from 2026 to 2036.

Demand Outlook for Congenital Hyperinsulinism Treatment Market in China

China is expected to lead growth at 5.8% through 2036, driven by expanding neonatal care infrastructure, improving genetic diagnostic capabilities, and increasing rare disease healthcare investment.

• Neonatal care expansion improves diagnostic identification.
• Genetic testing accessibility increases rare condition diagnosis.
• Healthcare investment supports treatment access improvement.

Future Outlook for Congenital Hyperinsulinism Treatment Market in India

India is expected to grow at 5.7% through 2036, reflecting expanding neonatal screening programs, growing pediatric healthcare capacity, and improving rare disease awareness.

• Neonatal screening programs improve early diagnosis.
• Pediatric healthcare capacity expansion supports treatment delivery.
• Rare disease awareness campaigns improve identification rates.

Opportunity Analysis of Congenital Hyperinsulinism Treatment Market in Germany

Germany is expected to grow at 5.6% through 2036, reflecting advanced neonatal intensive care, established rare disease centers, and strong pharmaceutical reimbursement.

• Advanced neonatal care supports early diagnosis and treatment.
• Rare disease centers deliver specialized management.
• Pharmaceutical reimbursement frameworks ensure treatment access.

In-depth Analysis of Congenital Hyperinsulinism Treatment Market in Brazil

Brazil is expected to grow at 5.5% through 2036, supported by expanding neonatal healthcare programs and improving rare disease diagnostic capabilities.

• Neonatal healthcare expansion supports diagnostic reach.
• Growing pediatric care infrastructure improves treatment access.
• International collaboration improves rare disease management.

Sales Analysis of Congenital Hyperinsulinism Treatment Market in USA

The USA is expected to grow at 5.4% through 2036, supported by advanced neonatal care, established rare disease treatment frameworks, and active clinical trial participation.

• Advanced neonatal care enables early treatment initiation.
• Rare disease frameworks support pharmaceutical development.
• Clinical trial activity drives novel treatment advancement.

Competitive Landscape and Strategic Positioning

• Xeris Pharmaceuticals holds an estimated 20.0% market share, leveraging its glucagon-based hypoglycemia management portfolio.
• Eli Lilly and Novo Nordisk hold positions through established endocrine and metabolic disease pharmaceutical portfolios.
• Emerging biotech companies are developing targeted therapies specifically designed for congenital hyperinsulinism subtypes.

Xeris Pharmaceuticals maintains market leadership through its glucagon-based treatment portfolio for hypoglycemia management. The company's ready-to-use glucagon formulations address emergency hypoglycemia episodes in congenital hyperinsulinism patients.

Eli Lilly and Novo Nordisk compete through established endocrine and metabolic disease portfolios that include glucagon, somatostatin analogs, and related products used in hyperinsulinism management.

Novartis AG participates through its broad pharmaceutical portfolio, while Rezolute, Inc. and Crinetics Pharmaceuticals develop targeted therapies specifically designed for hyperinsulinism indications.

Zealand Pharma and AmideBio are advancing novel peptide-based therapeutics that target specific aspects of insulin secretion regulation, representing emerging competitive entrants.

Key Companies in the Congenital Hyperinsulinism Treatment Market

Key global companies leading the congenital hyperinsulinism treatment market include:

• Xeris Pharmaceuticals (USA), Eli Lilly (USA), Novo Nordisk (Denmark), and Novartis AG (Switzerland) maintain strong positions through established endocrine and metabolic pharmaceutical portfolios.
• Rezolute, Inc. (USA), Eiger Biopharmaceuticals (USA), and Crinetics Pharmaceuticals (USA) hold positions through targeted hyperinsulinism therapy development.
• Hanmi Pharmaceutical (South Korea), AmideBio LLC (USA), and Zealand Pharma (Denmark) represent emerging competition through novel peptide and targeted therapeutic approaches.

Competitive Benchmarking: Congenital Hyperinsulinism Treatment Market

Company	Endocrine Portfolio	Pipeline Depth	Distribution Reach	CHI Focus
Xeris Pharmaceuticals	Narrow	Moderate	N. America	High
Eli Lilly	Broad	Broad	Global	Low
Novo Nordisk	Broad	Broad	Global	Low
Novartis AG	Broad	Broad	Global	Low
Rezolute, Inc.	Narrow	Moderate	Regional	High
Eiger Biopharmaceuticals	Narrow	Moderate	Regional	Moderate
Hanmi Pharmaceutical	Moderate	Moderate	Asia	Moderate
Crinetics Pharmaceuticals	Narrow	Moderate	Regional	High
AmideBio LLC	Narrow	Low	Regional	Moderate
Zealand Pharma	Narrow	Moderate	Europe	Moderate

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Congenital Hyperinsulinism Treatment Market

• In 2025, Xeris Pharmaceuticals expanded its ready-to-use glucagon formulation distribution to additional neonatal intensive care networks in Europe and East Asia.
• In 2026, Crinetics Pharmaceuticals initiated Phase 2 clinical trials for a targeted somatostatin receptor agonist designed for diazoxide-resistant congenital hyperinsulinism.

Key Players in the Congenital Hyperinsulinism Treatment Market

Major Global Players

• Xeris Pharmaceuticals, Inc.
• Eli Lilly
• Novo Nordisk
• Novartis AG
• Rezolute, Inc.
• Eiger Biopharmaceuticals
• Crinetics Pharmaceuticals, Inc.

Emerging Players/Startups

• Hanmi Pharmaceutical Co., Ltd.
• AmideBio LLC
• Zealand Pharma A/S
• De Motu Cordis
• Recordati Rare Diseases
• Ultragenyx Pharmaceutical
• Rhythm Pharmaceuticals
• Soleno Therapeutics
• Millendo Therapeutics

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 119.14 million to USD 213.37 million, at a CAGR of 6%
Market Definition	The congenital hyperinsulinism treatment market includes pharmaceuticals and surgical interventions for managing this rare genetic condition.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	China, India, Germany, Brazil, USA, 30 plus countries
Key Companies Profiled	Xeris Pharmaceuticals, Eli Lilly, Novo Nordisk, Novartis, Rezolute, Eiger Biopharmaceuticals, Crinetics Pharmaceuticals, Hanmi, AmideBio, Zealand Pharma
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Congenital Hyperinsulinism Treatment Market Market Segmented by Treatment Method:

• Drug Therapy
• Surgery

Congenital Hyperinsulinism Treatment Market Market Segmented by Application:

• Hospitals
• Clinics
• Others

Congenital Hyperinsulinism Treatment Market Market Segmented by End Use:

• Hospitals
• Specialty Clinics
• Home Care Settings

Congenital Hyperinsulinism Treatment Market Market Segmented by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Congenital Hyperinsulinism Treatment Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Rare Disease Global Health Estimates. WHO.
• 2. National Institutes of Health. (2024). NIH Genetic and Rare Diseases Information Center: Congenital Hyperinsulinism. NIH.
• 3. European Society for Paediatric Endocrinology. (2025). ESPE Clinical Practice Guidelines. ESPE.
• 4. USA Food and Drug Administration. (2025). FDA Orphan Drug Designations Database. FDA.
• 5. Congenital Hyperinsulinism International. (2024). CHI Patient Registry Data Report. CHI.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the size of the market and revenue projections from 2026 to 2036.
• Segmentation by treatment method, application, end use, and distribution channel.
• Regional and country-level demand analysis across key markets.
• Competitive landscape and pipeline assessment.
• Analysis of genetic diagnostic trends and patient identification.
• Regulatory landscape for orphan and rare disease therapeutics.
• Identification of growth opportunities in targeted therapy development.